Stability of acetylcysteine solution repackaged in oral syringes and associated cost savings

American Journal of Health-System Pharmacy

Volumn 64, Issue 7, 2007, Pages 762-766

  Kiser, Tyree H ^a   Oldland, Alan R ^b   Fish, Douglas N ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO HOSPITAL   (United States)

Author keywords

Acetylcysteine; Concentration; Economics; Mucolytic agents; Pharmacy; Photodecomposition; Stability; Storage; Syringes; Temperature; Time studies

Indexed keywords

ACETYLCYSTEINE; MUCOLYTIC AGENT;

COST BENEFIT ANALYSIS; COST CONTROL; DRUG PACKAGING; DRUG STABILITY; DRUG STORAGE; FLUORESCENCE; FLUORESCENT LIGHTING; FREEZING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MEASUREMENT; PHARMACY; PHOTODEGRADATION; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; ROOM TEMPERATURE; SYRINGE;

EID: 34047114342     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060425     Document Type: Review

References (13)

1. Mucomyst (acetylcysteine) package insert. Lake Forest, IL: Hospira Inc.; 2004 Nov.
2. Peterson RG, Rumack BH. Treating acute acetaminophen poisoning with acetylcysteine. JAMA. 1977; 237:2406-7.
3. Rumack BH, Peterson RC, Koch GG et al. Acetaminophen overdose. 662 cases with evaluation of oral acetylcysteine treatment. Arch Intern Med. 1981; 141(3 spec no.):380-5.
4. Zachwieja J, Zaniew M, Bobkowski W et al. Beneficial in vitro effect of N-acetyl-cysteine on oxidative stress and apoptosis. Pediatr Nephrol. 2005; 20:725-31.
5. Henderson A, Hayes P. Acetylcysteine as a cytoprotective antioxidant in patients with severe sepsis: potential new use for an old drug. Ann Pharmacother. 1994; 28:1086-8.
6. Sen CK, Rankinen T, Vaisanen S et al. Oxidative stress after human exercise: effect of N-acetylcysteine supplementation. J Appl Physiol. 1994; 76:2570-7.
7. Demedts M, Behr J, Buhl R et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005; 353:2229-42.
8. Marenzi G, Assanelli E, Marana I et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med. 2006; 354:2773-82.
9. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol. 2002; 89:356-8.
10. Kay J, Chow WH, Chan TM et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA. 2003; 289:553-8.
11. Rieutord A, Arnaud P, Dauphin JF et al. Stability and compatibility of an aerosol mixture including N-acetylcysteine, netilmicin and betamethasone. Int J Pharm. 1999; 190:103-7.
12. Shah VP, Midha KK, Findlay JW et al. Bioanalytical method validation-a revisit with a decade of progress. Pharm Res. 2000; 17:1551-7.
13. Lee TY, Chen CM, Lee CN et al. Compatibility and osmolality of inhaled N-acetylcysteine nebulizing solution with fenoterol and ipratropium. Am J Health-Syst Pharm. 2005; 62:828-33.